Merck Sharp & Dohme 10Q 2005 Q1 Quarterly report | SEC Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: ability, abnormal, abuse, accumulated, ACS, additionalVioxxProduct, adequacy, adjudication, adolescent, advantage, Advisor, affirmed, agent, AJCA, allVioxxProduct, allVioxxShareholder, analyzing, ANDA, andArcoxia, andVarivax, andVioxxForeign, antidilutive, antifungal, apparent, appellate, ARB, arbitration, Article, ascertain, asEzetroloutside, assessment, asthmatic, attainment, Austria, AWP, backup, BLA, black, BMS, borrowing, Bossidy, Boston, Bowen, Box, bronchospasm, calcium, cancel, capacity, Carolina, CDC, center, Central, CEO, chairperson, Chapter, check, Chesler, Childhood, cilastatin, Circuit, Clark, clerical, close, closed, closely, CMS, compliance, comply, conclusion, Congressional, consent, contributor, CozaarandHyzaarcompete, credit, denied, Director, disgorgement, Dobfar, Dohme, DOJ, dominant, drawn, earliest, earned, EC, Eldon, empirical, Employer, enforce, enhance, enhanced, environment, error, EU, evidence, exercise, extent, facility, failed, fall, Fallon, FAS, federalVioxxDerivative, filer, finasteride, forArcoxiabased, forArcoxiato, forCozaarandHyzaarwere, forEmend, forGardasil, forGardasilto, forHyzaar, formulation, forRotaTeq, forSingulairfor, forSingulairto, forZocordeclined, forZostavax, forZostavaxandRotaTeqfor, forZostavaxin, franchise, freight, FSP, gabaxadol, Gardasilsignificantly, German, governmental, Gruer, handling, HDL, hereinafter, holding, Honeywell, hypertension, hypertrophy, Identification, idle, imipenem, inactive, inappropriately, inclusion, indefinitely, indirectly, innovation, innovative, insufficiency, intake, intervene, intervened, inThe, Ireland, Italia, Italian, IV, joined, JPML, Kentucky, Lancet, Lawrence, leave, leaving, led, left, legislation, lieu, lifted, limited, linked, lipoprotein, longer, lose, low, LSC, LVH, manipulation, manufactureTienam, mark, MDL, MHRA, migration, minimum, mismanagement, mistakenly, MSD, Munich, nationwide, nausea, Nevada, newer, newly, North, notablyNexium, notified, objective, occur, occurred, occurrence, ofEmendfor, ofFosamax, ofFosamaxto, ofGardasil, ofPepcid, ofPepcidin, ofPrilosec, ofPropeciaand, ofTienam, ofVioxxlitigation, ofVioxxwhich, ofVytorinare, older, omeprazole, Oncology, opened, outstanding, overhead, paper, passage, passed, payable, permanently, petitioner, physician, pivotal, population, preliminarily, price, pricing, prohibited, prolonged, properly, Proxy, pursue, qui, reactivation, rebate, reconsider, reconsideration, reconsidered, referenced, refusal, rehearing, relevant, removed, renewed, requisite, rescheduled, retrospective, revolving, Richard, rule, ruled, ruling, Samuel, satisfy, Scandinavia, scheme, seal, sector, sequenced, Session, Sharp, shorter, spent, stabilized, Stanley, Station, statutorily, stepping, subsidiary, Suffolk, Supplementary, Supreme, Swedish, tam, theVioxxlegal, thevioxxlitigation, theVioxxProduct, Thier, threat, toVioxxin, transition, triglyceride, Turkey, twoVioxx, UK, underway, unenforceability, unknown, unrecognized, unsealing, upholding, ventricular, version, VioxxForeign, VioxxLitigation, VioxxProduct, virtually, virtue, vitamin, void, volume, vomiting, Washington, whereArcoxia, Whitehouse, Wisconsin, withVioxx, zoster

Removed: achievement, achieving, acid, add, added, agonist, AIIA, alternative, arising, attributable, Award, Banyu, began, biotechnology, calculated, candidate, Cardiology, causation, combination, commercialization, commercialize, comparable, compound, contract, curtailment, deacetylase, Del, demonstrated, density, designated, designed, determination, determining, developing, discontinued, discount, divestiture, effectively, effort, eliminate, eliminated, entity, equally, equivalent, exclude, exclusive, extensively, external, feasibility, FIN, floating, focusing, forCozaarandHyzaarincreased, fully, fundamentally, gaboxadol, goodwill, granting, heart, hedge, histone, HPS, hydroxamic, IMS, influenzatype, Interbank, interpretation, introduced, jointly, Journal, LIBOR, lipid, London, lymphoma, mechanism, merit, mg, milestone, mineral, model, modification, NVICP, ownership, payroll, peroxisome, planned, principal, privately, projected, ratably, receive, receptor, regained, regardingVioxx, repayment, residual, restated, revision, rounding, SAHA, separately, showed, sleep, spun, stage, studied, suberoylanilide, Summarized, summary, swap, switch, targeted, technological, term, track, tranche, translation, treating, unaffected, upfront, utilizing, variable, vest, vesting, VIE, wholesaler, world


Dated: May 9, 2005	/s/ Richard T. Clark

	Name:	Richard T. Clark
	Title:	Chief Executive Officer and President

Merck Sharp & Dohme 10-Q2005 Q1 Quarterly report

Content analysis